KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Revenue: 2009-2025

Historic Revenue for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Sep 2025 value amounting to $3.1 billion.

  • Vertex Pharmaceuticals' Revenue rose 10.99% to $3.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $11.7 billion, marking a year-over-year increase of 10.33%. This contributed to the annual value of $11.0 billion for FY2024, which is 11.66% up from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Revenue of $3.1 billion as of Q3 2025, which was up 3.77% from $3.0 billion recorded in Q2 2025.
  • Vertex Pharmaceuticals' 5-year Revenue high stood at $3.1 billion for Q3 2025, and its period low was $1.7 billion during Q1 2021.
  • In the last 3 years, Vertex Pharmaceuticals' Revenue had a median value of $2.7 billion in 2024 and averaged $2.7 billion.
  • Data for Vertex Pharmaceuticals' Revenue shows a peak YoY rose of 28.98% (in 2021) over the last 5 years.
  • Over the past 5 years, Vertex Pharmaceuticals' Revenue (Quarterly) stood at $2.1 billion in 2021, then climbed by 11.10% to $2.3 billion in 2022, then increased by 9.34% to $2.5 billion in 2023, then increased by 15.66% to $2.9 billion in 2024, then increased by 10.99% to $3.1 billion in 2025.
  • Its last three reported values are $3.1 billion in Q3 2025, $3.0 billion for Q2 2025, and $2.8 billion during Q1 2025.